Compositions and Methods for the Treatment of Immunodeficiency

Adma Biomanufacturing, LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 8 of these applications claim priority to application 62/069,589, filed Oct 28, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 9,107,906	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
US 9,714,283	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
US 9,815,886	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
US 9,969,793	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
US 10,683,343	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
US 11,339,206	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
US 11,780,906	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
US 12,473,351	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC In force Term ends Jan 8, 2035 · High confidence	Adma Biomanufacturing, LLC	In force	Term ends Jan 8, 2035	Term ends Jan 8, 2035	High confidence
Application 19/390,931	Compositions and Methods for the Treatment of Immunodeficiency Adma Biomanufacturing, LLC Pending Not granted	Adma Biomanufacturing, LLC	Pending	Not granted	not computed

9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

8 of these are in force and held by Adma Biomanufacturing, LLC.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.